Doxorubicin Market Doxorubicin Market Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Size, Share & Trends ...

Researchers from Stanford University and Rensselaer Polytechnic Institute have developed an advanced AI model that improves ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced positive topline results from pivotal Study BHV4157-206 ...

XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug applica ...

Over the last few years, artificial intelligence (AI) has emerged as a disruptive technology and is slowly changing almost every aspect of human life, including the healthcare sector and now, it’s ...

Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. See why I rate ...

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.

A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...

Since then, law enforcement agencies have approved 17,162 concealed carry permits on Long Island. Data shows less than 3% of ...

Zevra Therapeutics has won Food and Drug Administration approval of Miplyffa for Niemann-Pick disease type C, or NPC, making it the first drug cleared in the U.S. for the rare neurodegenerative ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.